Ph.D., Senior Director, Business Development, Biodesix, Inc.
Biography
Matthew Pink has over 12 years of experience in the pharma and diagnostics industries. He leads the biopharma services division at Biodesix, Inc. He previously served as Director of Business Development at CSL Behring followed by U.S. Director of Research External Innovation. Matthew has a B.S. in Biology from the University of Wisconsin-Madison and a Ph.D. in Neuroscience from the University of Colorado.
Talk
Clinical Dx Showcase:
Biodesix, Inc.
Biodesix, Inc. provides end-to-end diagnostic services for biopharma partners, including biomarker discovery, assay design and development, fit-for-purpose regulatory strategies, clinical trial testing, commercialization, and companion diagnostic capabilities. For biopharmaceutical therapeutics in development, we uncover novel insights about tumor biology and patient immune response.
Blood-based multi-omics to guide IO treatment strategy
A case study on how Biodesix utilizes genomics and proteomics to identify patients for immunotherapy.
Session Abstract – PMWC 2023 Silicon Valley
Showcase Track S2 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-4.45 P.M.,Showcase Track S2 - January 27 9.00 A.M.-2.15 P.M.
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
